Veraxa Biotech AG is an innovative biotechnology company dedicated to developing transformative therapeutic solutions that address critical medical needs. By leveraging advanced biotechnological platforms, Veraxa is advancing a promising pipeline of novel drug candidates across multiple therapeutic areas. The firm is committed to scientific excellence and its strategic vision focuses on creating proprietary technologies aimed at delivering breakthrough treatments, thereby enhancing patient care globally. As it moves through key clinical development stages, Veraxa is strategically positioned to attract partnerships and investments to bolster its growth in the evolving biotech sector.
| Revenue (TTM) | 23,430 |
| Gross Profit (TTM) | 15,460 |
| EBITDA | $-64.24M |
| Operating Margin | -282663.00% |
| Return on Equity | -871.00% |
| Return on Assets | -50.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.29 |
| Price-to-Book | 89.31 |
| Price-to-Sales (TTM) | 6700.36 |
| EV/Revenue | 6910.74 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $141.41M |
| Float | $3.84M |
| % Insiders | 69.92% |
| % Institutions | 0.86% |
Volatility is currently expanding
VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.
Veraxa is shifting away from animal testing to get drugs to market faster, calling it ‘not just a regulatory obligation, but a scientific opportunity.'
Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately.
ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent portfolio. During the first half of 2026, first patent applications were filed to cover the Company's new generation of technologies including its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) platforms and therapeutic programs derived from them.
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately. Christoph Erkel, previously Vice President of Research & Development at VERAXA, will apply his extensive management expertise in R&D to direct and accelerate development of the company's proprietary BiTAC® (bi-targeted tumor-associated cytotoxicity) platform technologies, with the goal of developing safer and more effective cancer treatments for patients with solid tumors. He succeeds Rick Austin, Ph.D., who will be leaving the company after a successful transition period.
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed non-clinical development plan for its most-advanced development program based on its proprietary BiTAC-TCE technology. In the PEI's Scientific Advice procedure, drug developers can consult with regulatory experts on how to best evaluate their new drug candidates with a key focus on safety and tolerability.
ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern R&D recognized for pioneering the use of artificial intelligence (AI) and bioinformatics for precision medicine, to support VERAXA's growing BiTAC® pipeline of t cell engagers (TCEs) and antibody drug conjugates (ADCs).
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds Torsten Bürgermeister.
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first six months of 2026, we have made substantial progress in honing our pipeline and partnering strategy.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VRXA and any ticker you trade — then tracks every position and per-strategy win rate.
